Quratis, specialization in tuberculosis vaccine company

The company expects that Quratis's main contract on the Term Sheet for tuberculosis vaccines for adults and adolescents, which was signed last year with Indonesian Biopharma, will be completed in this year. 

“We scheduled to sign the main contract in the first half of this year, but it has been delayed due to the Covid19, said Kwan-Goo Cho, CEO of the company.

Quratis is also working closely with major partners such as China, Russia, and the Philippines to export technology, cooperate development and attract investment of tuberculosis vaccines. "As countries are in high demand for tuberculosis vaccines, local partners are showing great interest in the tuberculosis vaccine technology that we have. From the second half of this year, tangible results will be drawn." said Kwan-Goo Cho. 

In the first half of this year, Quratis completed its 2a clinical trial of tuberculosis vaccine in the South Korea and is currently analyzing the results. The final report regarding the clinical trial is expected in August. Clinical 2b for tuberculosis vaccine is planned to be carried out in Korea, Russia, Indonesia and the Philippines starting next year. The company explains that if the vaccine development is carried out as scheduled, it could reach commercialization of tuberculosis vaccines for adults and adolescents for the first time in the world as early as 2024.